Upstream Bio, Inc.
For the period ended Sep 30, 2026. Filed Nov 10, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 10, 2026
UPB$3.38-5.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statement of Stockholders’ Equity
(Amounts in thousands, except share amounts)
| Common Stock · Additional Paid-in · Accumulated · AccumulatedOther Comprehensive · Total Stockholders' | ||||||
|---|---|---|---|---|---|---|
| Shares | Amount | Capital | Deficit | Income (Loss) | Equity | |
| Balances at December 31, 2024 | 53,603,398 | $53 | $660,604 | $(190,780) | $(25) | $469,852 |
| Issuance of common stock under stock plans | 37,497 | — | — | — | — | — |
| Stock-based compensation expense | — | — | 2,635 | — | — | 2,635 |
| Unrealized gain on available-for-sale securities, net of tax | — | — | — | — | 393 | 393 |
| Net loss | — | — | — | (27,270) | — | (27,270) |
| Balances at March 31, 2025 | 53,640,895 | 53 | 663,239 | (218,050) | 368 | 445,610 |
| Issuance of common stock under stock plans | 157,256 | 1 | 611 | — | — | 612 |
| Stock-based compensation expense | — | — | 2,597 | — | — | 2,597 |
| Unrealized loss on available-for-sale securities, net of tax | — | — | — | — | (110) | (110) |
| Net loss | — | — | — | (39,966) | — | (39,966) |
| Balances at June 30, 2025 | 53,798,151 | 54 | 666,447 | (258,016) | 258 | 408,743 |
| Issuance of common stock under stock plans | 201,371 | 2 | 758 | — | — | 760 |
| Stock-based compensation expense | — | — | 2,594 | — | — | 2,594 |
| Unrealized gain on available-for-sale securities, net of tax | — | — | — | — | 235 | 235 |
| Net loss | — | — | — | (33,748) | — | (33,748) |
| Balances at September 30, 2025 | 53,999,522 | $56 | $669,799 | $(291,764) | $493 | $378,584 |
Condensed consoli dated statement of stockholders’ equity
(Amounts in thousands, except share amounts)
| Common Stock · Additional Paid-in · Accumulated · AccumulatedOther Comprehensive · Total Stockholders' | ||||||
|---|---|---|---|---|---|---|
| Shares | Amount | Capital | Deficit | Income (Loss) | Equity | |
| Balances at December 31, 2025 | 54,237,750 | $54 | $673,410 | $(334,223) | $530 | $339,771 |
| Issuance of common stock under stock plans | 182,236 | — | 598 | — | — | 598 |
| Stock-based compensation expense | — | — | 4,647 | — | — | 4,647 |
| Unrealized loss on available-for-sale securities, net of tax | — | — | — | — | (430) | (430) |
| Net loss | — | — | — | (40,591) | — | (40,591) |
| Balances at March 31, 2026 | 54,419,986 | 54 | 678,655 | (374,814) | 100 | 303,995 |
| Issuance of common stock in connection with at-the-market program, net of commissions | 239,797 | — | 2,083 | — | — | 2,083 |
| Issuance of common stock under stock plans | 111,258 | — | 450 | — | — | 450 |
| Stock-based compensation expense | — | — | 4,354 | — | — | 4,354 |
| Unrealized loss on available-for-sale securities, net of tax | — | — | — | — | (223) | (223) |
| Net loss | — | — | — | (39,702) | — | (39,702) |
| Balances at June 30, 2026 | 54,771,041 | 54 | 685,542 | (414,516) | (123) | 270,957 |
| Issuance of common stock under stock plans | 40,350 | — | 69 | — | — | 69 |
| Stock-based compensation expense | — | — | 4,345 | — | — | 4,345 |
| Unrealized loss on available-for-sale securities, net of tax | — | — | — | — | (204) | (204) |
| Net loss | — | — | — | (41,192) | — | (41,192) |
| Balances at September 30, 2026 | 54,811,391 | $54 | $689,956 | $(455,708) | $(327) | $233,975 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.